

SELL TP: Rs 750 | ¥ 15%

MAHANAGAR GAS

Oil & Gas

Margins surge but volume recovery lags peers

Mahanagar Gas's (MAHGL) Q2FY21 PAT outperformed at Rs 1.4bn (-46% YoY, +3x QoQ). Q2 highlights: (a) Volumes were above estimates at 2.1mmscmd (-31% YoY), recovering 88% QoQ. (b) EBITDA margins swelled to Rs 11.6/scm (+17% YoY), driving the overall beat on earnings. We expect the extended lockdown in the Mumbai region to keep CNG volumes sluggish until H1FY22, leading us to cut FY21/FY22 earnings by 8%/13%. Our Sep'21 DCF-based TP remains unchanged at Rs 750. Maintain SELL.

Volume recovery lags peers: MAHGL's CNG volumes surged 2.6x QoQ to 117mmscm (-42% YoY) in Q2, but relatively underperformed peers. Revival to pre-Covid demand levels could be delayed to H1FY22 considering the extended lockdown in Mumbai (buses being hit the most as school reopening stands postponed to FY22). Over the long term, rising infrastructure constraints in Mumbai for CNG outlet expansion and improving alternate travel options (metro) suggest volume growth may remain weak.

Margins surge: Q2 EBITDA margin expanded to Rs 11.6/scm as CNG volumes increased, and MAHGL used its pricing advantage primarily to limit the YoY impact on earnings. We raise our margin estimates to ~Rs 11/scm (from Rs 10 earlier) but trim volume assumptions by ~10% over FY21/FY22. These margins may not sustain beyond FY21 as MAHGL would need to chase volume growth, especially in the industrial and commercial PNG segments.

Maintain SELL: Muted FY20-FY23 earnings trends accompanied by recurring concerns over CNG volume growth are likely to add fuel to the sustained derating in multiples seen over the last quarter. MAHGL lags peers on volume growth and would need to compromise on margins eventually. Expansion into new areas could also be delayed due to the pandemic impact.

KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue (Rs mn)	27,911	29,721	24,145	29,290	35,006
EBITDA (Rs mn)	8,855	10,528	9,936	10,725	12,384
Adj. net profit (Rs mn)	5,464	7,935	6,875	7,254	8,349
Adj. EPS (Rs)	55.3	80.3	69.6	73.4	84.5
Adj. EPS growth (%)	14.3	45.2	(13.4)	5.5	15.1
Adj. ROAE (%)	24.3	29.7	22.2	21.4	22.5
Adj. P/E (x)	15.9	10.9	12.6	12.0	10.4
EV/EBITDA (x)	9.7	8.1	8.5	7.8	6.8

Source: Company, BOBCAPS Research

BOB Capital Markets Ltd is a wholly owned subsidiary of Bank of Baroda

Important disclosures, including any required research certifications, are provided at the end of this report.

13 November 2020

Rohit Ahuja | Harleen Manglani research@bobcaps.in

Ticker/Price	MAHGL IN/Rs 879
Market cap	US\$ 1.2bn
Shares o/s	99mn
3M ADV	US\$ 12.4mn
52wk high/low	Rs 1,246/Rs 664
Promoter/FPI/DII	33%/30%/38%
Source: NSE	

STOCK PERFORMANCE



Source: NSE





FIG 1 – QUARTERLY PERFORMANCE

Y/E March (Rs mn)	Q2FY21	Q2FY20	Y₀Y (%)	Q1FY21	Q₀Q (%)	H1FY21	H1FY20	Y₀Y (%)
Net sales	5,067	7,836	(35.3)	2,618	93.6	7,685	15,411	(50.1)
Raw Material Consumed	1,771	3,785	(53.2)	988	79.2	2,759	7,267	(62.0)
% of sales	34.9	48.3	-	37.8	-	35.9	47.2	-
Other expenditure	1,086	1,317	(17.6)	829	30.9	1,915	2,641	(27.5)
% of sales	21.4	16.8	-	31.7	-	24.9	17.1	-
EBITDA	2,211	2,734	(19.1)	800	176.4	3,011	5,502	(45.3)
EBITDA margin (%)	43.6	34.9	-	30.6	-	39.2	35.7	-
EBITDA (Rs/scm)	11.6	9.9	17.0	7.9	46.8	10.3	10.1	2.3
Depn and amortization	425	391	8.6	423	0.5	847	763	11.0
Interest	20	15	40.0	15	32.7	36	28	26.2
Other income	184	230	(19.8)	245	(24.8)	430	433	(0.9)
Profit Before Tax	1,950	2,558	(23.8)	607	221.2	2,558	5,145	(50.3)
Provision for tax	507	(148)	(443.0)	155	227.7	662	736	(10.1)
-effective tax rate (%)	26.0	(5.8)	-	25.5	-	25.9	14.3	-
PAT (reported)	1,443	2,706	(46.7)	452.5	219.0	1,896	4,409	(57.0)
Total income	1,450	2,691	(46.1)	447	224.2	1,887	4,409	(57.2)
Reported EPS (Rs)	14.6	27.4	(46.7)	4.6	219.0	19.2	44.5	(56.9)

Source: Company, BOBCAPS Research

FIG 2 – VOLUME BREAKUP

	Q2FY21	Q2FY20	Y₀Y (%)	Q1FY21	Q₀Q (%)	H1FY21	H1FY20	Y₀Y (%)
CNG Volumes (mmscm)	117	203	(42.0)	44	168.6	161	400	(59.7)
PNG Volumes (mmscm)	73	73	(0.1)	58	27.3	131	147	(10.6)
Industrial/Commercial	31	38	(19.9)	19	65.3	49	75	(34.3)
Domestic	43	35	21.6	39	9.2	82	71	14.2
Total Volumes (mmscm)	191	276	(30.9)	101	88.3	292	546	(46.5)
Total Volumes (mmscmd)	2.07	3.00	(30.9)	1.10	88.3	1.59	2.98	(46.8)

Source: Company, BOBCAPS Research


FIG 3 – OPERATING PERFORMANCE

	Q2FY21	Q2FY20	Y₀Y (%)	Q1FY21	Q₀Q (%)	H1FY21	H1FY20	Y₀Y (%)
Avg realisation (Rs/scm)	26.6	28.4	(6.4)	25.8	2.8	26.3	28.2	(6.8)
Gas cost (Rs/scm)	9.3	13.7	(32.3)	9.8	(4.9)	9.5	13.3	(28.5)
Gross spreads (Rs/scm)	17.3	14.7	17.7	16.1	7.5	16.8	14.9	12.6
CNG realisation (Rs/kg)	35.0	35.8	(2.4)	35.1	(0.3)	35.0	35.7	(1.8)
PNG realisation (Rs/scm)	28.1	31.2	(9.9)	25.8	8.7	27.0	31.8	(15.3)
EBITDA (Rs/scm)	11.6	9.9	17.0	7.9	46.8	10.3	10.1	2.3
Other operating costs (Rs/scm)	5.7	4.8	19.3	8.2	(30.5)	6.5	4.8	34.1

Source: Company, BOBCAPS Research



FIG 4 - CNG AND PNG REALISATIONS



Source: Company, BOBCAPS Research





FIG 5 – VOLUME COMPOSITION

Source: Company, BOBCAPS Research

FIG 6 - VOLUME GROWTH OUTLOOK



Source: Company, BOBCAPS Research



Valuation methodology

Muted FY20-FY23 earnings trends accompanied by recurring concerns over CNG volume growth are likely to add fuel to the sustained derating in multiples seen over the last quarter. MAHGL lags peers on volume growth and would need to compromise on margins eventually. Expansion into new areas could also be delayed due to the pandemic impact.

We expect the extended lockdown in the Mumbai region to keep CNG volumes sluggish until H1FY22, leading us to cut FY21/FY22 earnings by 8%/13%. Our Sep'21 DCF-based target price remains unchanged at Rs 750. Maintain SELL.

FIG 7 – REVISED ESTIMATES

(Rs mn) -		FY21E			FY22E			FY23E	
(Ks mn)	Old	New	Var (%)	Old	New	Var (%)	Old	New	Var (%)
Revenue	27,877	24,145	(13.4)	32,819	29,290	(10.8)	34,866	35,006	0.4
EBITDA	10,626	9,936	(6.5)	12,112	10,725	(11.5)	12,382	12,384	0.0
EBITDA margin (%)	38.1	41.2	-	36.9	36.6	-	35.5	35.4	-
PAT	7,437	6,875	(7.6)	8,381	7,254	(13.4)	8,408	8,349	(0.7)
PAT margin (%)	26.7	28.5	-	25.5	24.8	-	24.1	23.9	-
EPS (Rs)	75.3	69.6	(7.6)	84.8	73.4	(13.4)	85.1	84.5	(0.7)

Source: Company, BOBCAPS Research

FIG 8 - VALUATION SUMMARY

Valuation parameters	(Rs mn)
WACC (%)	9.6
Terminal Year growth (%)	2.0
PV of FCF	14,870
PV of terminal value	47,331
Firm Value	62,200
Less Net Debt	(11,899)
Equity value	74,099
Equity Value (Rs/share)	750

Source: BOBCAPS Research

FIG 9 – RELATIVE STOCK PERFORMANCE





Key risks

Key upside risks to our estimates are:

- above-expected operating margins,
- higher-than-estimated volume growth for CNG and PNG, and
- faster-than-expected expansion of MAHGL's areas of operation on successful placement of winning bids in PNGRB's upcoming CGD rounds.



FINANCIALS

Income Statement

Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue	27,911	29,721	24,145	29,290	35,006
EBITDA	8,855	10,528	9,936	10,725	12,384
Depreciation	(1,259)	(1,617)	(1,700)	(1,902)	(2,144)
EBIT	7,595	8,911	8,236	8,823	10,240
Net interest income/(expenses)	(3)	(65)	0	0	0
Other income/(expenses)	777	990	943	862	907
EBT	8,369	9,835	9,179	9,684	11,147
Income taxes	(2,905)	(1,900)	(2,304)	(2,431)	(2,798)
Reported net profit	5,464	7,935	6,875	7,254	8,349
Adjusted net profit	5,464	7,935	6,875	7,254	8,349

Balance Sheet

Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21E	FY22E	FY23E
Accounts payables	1,524	1,318	616	824	1,013
Other current liabilities	6,637	8,571	6,228	8,138	9,916
Provisions	212	263	253	267	307
Other liabilities	2,048	1,607	2,075	2,569	3,137
Equity capital	988	988	988	988	988
Reserves & surplus	23,001	28,539	31,391	34,401	37,865
Shareholders' fund	23,989	29,527	32,379	35,389	38,853
Total liabilities and equities	34,410	41,285	41,551	47,186	53,226
Cash and cash eq.	2,988	2,295	3,404	2,786	2,798
Accounts receivables	996	685	595	722	863
Inventories	191	186	132	160	192
Other current assets	2,168	1,268	1,268	1,268	1,268
Investments	6,736	11,495	8,495	10,495	12,495
Net fixed assets	17,588	20,446	22,205	24,924	27,815
CWIP	3,697	4,865	5,406	6,784	7,749
Total assets	34,364	41,239	41,505	47,140	53,180

Source: Company, BOBCAPS Research



Cash Flows

Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21E	FY22E	FY23E
Net income + Depreciation	6,723	9,552	8,576	9,156	10,493
Changes in working capital	1,051	2,995	(2,912)	1,977	1,835
Other operating cash flows	(486)	(1,420)	(475)	(368)	(338)
Cash flow from operations	7,288	11,128	5,188	10,765	11,990
Capital expenditures	(3,658)	(5,644)	(4,000)	(6,000)	(6,000)
Change in investments	141	(4,759)	3,000	(2,000)	(2,000)
Cash flow from investing	(3,517)	(10,403)	(1,000)	(8,000)	(8,000)
Debt raised/repaid	(12)	0	0	0	0
Dividends paid	(3,197)	(4,643)	(4,023)	(4,244)	(4,885)
Other financing cash flows	1,508	3,225	943	862	907
Cash flow from financing	(1,701)	(1,418)	(3,079)	(3,382)	(3,978)
Changes in cash and cash eq.	2,070	(694)	1,109	(618)	12
Closing cash and cash eq.	2,989	2,295	3,404	2,786	2,798

Per Share

Y/E 31 Mar (Rs)	FY19A	FY20A	FY21E	FY22E	FY23E
Reported EPS	55.3	80.3	69.6	73.4	84.5
Adjusted EPS	55.3	80.3	69.6	73.4	84.5
Dividend per share	27.7	40.2	34.8	36.7	42.3
Book value per share	242.9	298.9	327.8	358.3	393.3

Valuations Ratios

Y/E 31 Mar (x)	FY19A	FY20A	FY21E	FY22E	FY23E
EV/Sales	3.1	2.9	3.5	2.9	2.4
EV/EBITDA	9.7	8.1	8.5	7.8	6.8
Adjusted P/E	15.9	10.9	12.6	12.0	10.4
P/BV	3.6	2.9	2.7	2.5	2.2

DuPont Analysis

Y/E 31 Mar (%)	FY19A	FY20A	FY21E	FY22E	FY23E
Tax burden (Net profit/PBT)	65.3	80.7	74.9	74.9	74.9
Interest burden (PBT/EBIT)	110.2	110.4	111.5	109.8	108.9
EBIT margin (EBIT/Revenue)	27.2	30.0	34.1	30.1	29.3
Asset turnover (Revenue/Avg TA)	86.6	78.6	58.4	66.1	69.8
Leverage (Avg TA/Avg Equity)	1.4	1.4	1.3	1.3	1.4
Adjusted ROAE	24.3	29.7	22.2	21.4	22.5

Source: Company, BOBCAPS Research | Note: TA = Total Assets



Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
YoY growth (%)					
Revenue	25.0	6.5	(18.8)	21.3	19.5
EBITDA	13.5	18.9	(5.6)	7.9	15.5
Adjusted EPS	14.3	45.2	(13.4)	5.5	15.1
Profitability & Return ratios (%)					
EBITDA margin	31.7	35.4	41.2	36.6	35.4
EBIT margin	27.2	30.0	34.1	30.1	29.3
Adjusted profit margin	19.6	26.7	28.5	24.8	23.9
Adjusted ROAE	24.3	29.7	22.2	21.4	22.5
ROCE	22.1	26.9	19.9	19.5	20.7
Working capital days (days)					
Receivables	12	10	10	8	8
Inventory	6	5	6	4	4
Payables	25	27	25	14	15
Ratios (x)					
Gross asset turnover	1.1	1.0	0.7	0.8	0.8
Current ratio	0.8	0.4	0.8	0.5	0.5
Net interest coverage ratio	2,352.9	136.5	0.0	0.0	0.0
Adjusted debt/equity	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)

Source: Company, BOBCAPS Research



Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


ADD – Expected return from >+5% to +15%

REDUCE – Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

RATINGS AND TARGET PRICE (3-YEAR HISTORY): MAHANAGAR GAS (MAHGL IN)



B - Buy, A - Add, R - Reduce, S - Sell, H - Hold

Rating distribution

As of 31 October 2020, out of 88 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 42 have BUY ratings, 14 have ADD ratings, 10 are rated REDUCE and 22 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH00000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations

MAHANAGAR GAS



expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.